LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

554.29 -1.05

Buy Sell

Overview

Share price change

24h

Current

Min

544.23

Max

559.61

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+4.2% upside

Market Stats
By TradingEconomics
Market Cap	3.5B 13B
Previous open	555.34
Previous close	554.29

News Sentiment

By Acuity

50%

169 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 gru 2025, 23:46 UTC

Market Talk

Gold Edges Higher, Aided by Fed Rate-Cut Prospects -- Market Talk

16 gru 2025, 23:38 UTC

Market Talk

Nikkei May Rise on Possible Bargain-Hunting Interest -- Market Talk

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos: Sale Delivered Cash, Reduced Future Decommissioning Exposure

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Stake in Petrel Fields, 100% of Tern Fields to Eni Australia

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos: A$40M Upfront Consideration, Up to A$20M in Contingent Payments

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Operated Interest in Mahalo JV to Comet Ridge

16 gru 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Santos Divests Two Noncore Assets as Part of Portfolio Optimization

16 gru 2025, 22:25 UTC

Acquisitions, Mergers, Takeovers

Westgold's Indicative Timetable Points to Early February Completion

16 gru 2025, 22:24 UTC

Acquisitions, Mergers, Takeovers

Westgold: Divestment Aligns With Broader Corporate Strategy

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold: Deferred Payment Based on Performance Hurdles

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold Will Receive A$15M Cash, A$19.6M in Alicanto Shares

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold to Receive A$30M Deferred Payment in Cash or Shares

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Divesting Noncore Operating Asset for A$64.6M

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Agrees to Sell Mt Henry-Selene Project to Alicanto Minerals

16 gru 2025, 21:53 UTC

Earnings

Lennar Misses Earnings Estimates. The Stock Is Dropping. -- Barrons.com

16 gru 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- 2nd Update

16 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- Update

16 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises to Buy LSI Group for About $205M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Sales $327.5M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Adj EPS 65c >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q EPS 55c >WOR

16 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises Agrees To Acquire Leading Metal Roof Components Manufacturer LSI Group >WOR

16 gru 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

Ecolab Closes Acquisition Of Ovivo's Electronics Ultrapure Water Business >ECL

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Reject Paramount Offer As Soon As Wednesday, Sources Say -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Recommend Existing Netflix Deal, Sources Say -- WSJ

16 gru 2025, 20:44 UTC

Market Talk

Russia-Ukraine Peace Efforts Send Crude to Near 5-Year Low -- Market Talk

16 gru 2025, 20:04 UTC

Market Talk

U.S. Natural Gas Extends Weather-Driven Losing Streak -- Market Talk

16 gru 2025, 20:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

4.2% upside

12 Months Forecast

Average 584.09 USD 4.2%

High 670 USD

Low 523 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

169 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.